Superworth

Connect Biopharma EPS CNTB

Diluted earnings per share by quarter and over the last twelve months, from 2024.

Last 12 months, to Jun 30, 2026
−$1.19
Latest quarter, Q2 FY26
−$0.27
Fiscal year 2025
−$1.00

Connect Biopharma's earnings per share was −$1.19 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.27.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$1.00n/a
FY2024−$0.28n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.27n/a−$1.19
Q1 FY26−$0.34n/a−$1.15
Q4 FY25−$0.27n/a−$1.00
Q3 FY25−$0.31n/a−$0.89
Q2 FY25−$0.23−185%−$0.81
Q1 FY25−$0.19n/a−$0.31
Q4 FY24−$0.16n/a−$0.28
Q3 FY24−$0.23n/an/a
Q2 FY24$0.27n/an/a
Q1 FY24−$0.16n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Connect Biopharma's size, closest first, today.

CompanyEPS, 12 monthsGrowth
CNTBConnect Biopharma−$1.19
ATNMActinium Pharmaceuticals$0.36
SPROSpero Therapeutics$0.11
LFVNLifevantage$0.40−46% a year
NATRNatures Sunshine Products$1.01+36% a year
ARVNArvinas$0.16
Peer median$0.36

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Connect Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.